Effects of Long-Term Oral Administration of Polymeric Microcapsules Containing Tyrosinase on Maintaining Decreased Systemic Tyrosine Levels in Rats

Journal of Pharmaceutical Sciences

Volumn 93, Issue 4, 2004, Pages 831-837

  Yu, Binglan ^a   Chang, Thomas Ming Swi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; Enzymes; Gene therapy; Macromolecular drug delivery; Microcapsules; Oral drug delivery; Polymeric drug carrier; Protein delivery

Indexed keywords

DRUG CARRIER; MONOPHENOL MONOOXYGENASE; POLYMER; PYROXYLIN; TYROSINE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; INBORN ERROR OF METABOLISM; INTESTINE; LONG TERM CARE; MACROMOLECULE; MALE; MELANOMA; MICROCAPSULE; MICROENCAPSULATION; NAUSEA; NONHUMAN; RAT; TYROSINEMIA; VOMITING; WEIGHT REDUCTION;

EID: 1842587412     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10593     Document Type: Article

References (28)

1. Katsambas A, Nicolaidou E. 1996. Cutaneous malignant melanoma and sun exposure. Arch Dermatol 132:444-450.
2. Caraceni A, Gangeri L, Martini C, Belli F, Brunellic C, Baldini M, Mascheroni L, Lenisa L, Cascinelli N. 1998. Neurotoxicity of interferon-α in melanoma therapy. Cancer 83:482-489.
3. Dickler MN, Coit DG, Meyers ML. 1997. Adjuvant therapy of malignant melanoma. Surg Oncol Clin North Am 6:793-812.
4. Johnson TM, Yahanda AM, Chang AE, Fader DJ, Sondak VK. 1998. Advances in melanoma therapy. J Am Acad Dermatol 38:731-741.
5. Elmer GW, Meadows GG, Linden C, Digiovanni J, Holcenberg JS. 1976. Influence of tyrosine phenollyase on growth of B-16 melanoma. Pigment Cell 2:339-346.
6. Meadows GG, Oeser DE. 1983. Response of B16 melanoma-bearing mice to varing dietary levels of phenylalanine and tyrosine. Nutr Rep Int 28:1073-1082.
7. Russo PA, Mitchell GA, Tanguay RM. 2001. Tyrosinemia: A review. Pediatr Dev Pathol 4:212-221.
8. Chang TMS, Poznansky MJ. 1968. Semipermeable microcapsules containing catalase for enzyme replacement in acatalasemic mice. Nature 218:242-245.
9. Bourget L, Chang TMS. 1986. Phenylalanine ammonia-lyase microencapsulated in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. Biochim Biophys Acta 883:423-438.
10. Bourget L, Chang TMS. 1989. Effects of oral administration of artificial cells microencapsulated phenylalanine ammonia-lyase on intestinal amino acids of phenylketonuric rats. Biomater Artif Cells Artif Organs 17:161-181.
11. Chang TMS, Bourget L, Lister C. 1995. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif Cells Blood Subst Immobil Biotechnol 23:1-21.
12. Shu CD, Chang TMS. 1981. Tyrosinase microencapsulated within artificial cells for detoxification in liver failure: II. In vivo studies in fulminant hepatic failure rats. Int J Artif Organs 4:82-85.
13. Yu B, Chang TMS. 2002. In vitro enzyme kinetics of microencapsulated tyrosinase. Artif Cells Blood Subst Immobil Biotechnol 30:533-546.
14. Chang TMS. 1964. Semipermeable microcapsules. Science 146:524-525.
15. Chang TMS, MacIntosh FC, Mason SG. 1966. Semipermeable aqueous microcapsules. Preparation and properties. Can J Physiol Pharmacol 44:115-128.
16. Chang TMS. 1972. Artificial cells. Springfield: CC Thomas.
17. Waalkes TP, Udenferiend S. 1957. A fluorometric method for the estimation of tyrosine in plasma and tissues. J Lab Clin Med 11:733-736.
18. Fisher MJ, Pogson CI. 1984. The determination of flux through phenylalanine hydroxylase and homogentisate oxidase in isolated hepatocytes. Bioscience Rep 4:835-841.
19. Rosner B. 2000. Fundamentals of biostatistics, 5th ed. Pacific Grove, CA: Duxbury.
20. Lorincz AB, Kuttner RE, Brandt MB. 1968. Tumor response to phenylalanine-tyrosine limited diets. J Am Dietet Assoc 54:198-205.
21. Norris JR, Meadows GG, Massey LK, Starkey JR, Sylvester DM, Liu SY. 1990. Tyrosine and phenylalanine-restricted formula diet augments immunocompetence in healthy human. Am J Clin Nutr 51:188-196.
22. Uhlenkott CE, Huijzer JC, Cardeiro DJ, Elstad CA, Meadows GG. 1996. Attachment, invasion, chemotaxis, and proteinase expression of B16-BL6 melanoma cells exhibiting a low metastatic phenotype after exposure to dietary restriction of tyrosine and phenylalanine. Clin Exp Metast 14:125-137.
23. Pelayo BA, Fu YM, Meadows GG. 2001. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. Int J Oncol 18:877-883.
24. Inoue S, Hasegawa K, Wakamatsu K, Ito S. 1998. Comparison of antimelanoma effects of 4-S-cysteaminylphenol and its homologues. Melanoma Res 8:105-112.
25. Jordan AM, Khan TH, Osborn H, Photiou A, Riley PA. 1999. Melanocyte-directed enzyme prodrug therapy (MDEPT): Development of a targeted treatment for malignant melanoma. Bioorgan Med Chem 7:1775-1780.
26. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. 2000. T-cell recognition of melanoma-associated antigens. J Cell Physiol 182:323-331.
27. Chang TMS, Prakash S. 2001. Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms. Mol Biotechnol 17:249-260.
28. Palmour RM, Goodyer P, Reade T, Chang TMS. 1989. Microencapsulated xanthine oxidase as experimental therapy in Lesch-Nyhan disease. Lancet 2:687-688.